Review



cd39 blockingmab  (Bio-Rad)


Bioz Verified Symbol Bio-Rad is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Bio-Rad cd39 blockingmab
    Figure 4. The phenotype and function of CD161þ CTLs. A, Heat map displaying expression values of discriminative genes between KLRB1 and KLRB1þ CTLs (from clusters 0, 2, 3, and 9) based on the data from single-cell RNA sequencing. B, Scores for the terminal exhaustion signature, tissue-resident memory T-cell signature, and chemokine/IFNg signature in KLRB1 and KLRB1þ CTLs based on the data from single-cell RNA sequencing. C, Coexpression of cytotoxic cytokines and inhibitory receptors on CD161 or CD161þ CTLs in OPSCC biopsies (n ¼ 13–19) via flow cytometry, paired Student t test. D, MFI of cytotoxic cytokines coexpressed on CD161 or CD161þ CTLs treated with PD-1 or <t>CD39</t> blocking antibodies in OPSCC biopsies (n ¼ 7–8), paired Student t test. E, MFI of IFNg coexpressed on CD161þ CTLs treated with CD161-blocking antibodies for 72 hours in HPVþ biopsies (n ¼ 3) and blood samples (n ¼ 4), paired Student t test. , P < 0.05; , P < 0.01; , P < 0.001. n.s.: no statistical significance.
    Cd39 Blockingmab, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 94/100, based on 15 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd39 blockingmab/product/Bio-Rad
    Average 94 stars, based on 15 article reviews
    cd39 blockingmab - by Bioz Stars, 2026-05
    94/100 stars

    Images

    1) Product Images from "CD161 characterizes an inflamed subset of cytotoxic T lymphocytes associated with prolonged survival in human papillomavirus-driven oropharyngeal cancer"

    Article Title: CD161 characterizes an inflamed subset of cytotoxic T lymphocytes associated with prolonged survival in human papillomavirus-driven oropharyngeal cancer

    Journal: Cancer Immunology Research

    doi: 10.1158/2326-6066.cir-22-0454

    Figure 4. The phenotype and function of CD161þ CTLs. A, Heat map displaying expression values of discriminative genes between KLRB1 and KLRB1þ CTLs (from clusters 0, 2, 3, and 9) based on the data from single-cell RNA sequencing. B, Scores for the terminal exhaustion signature, tissue-resident memory T-cell signature, and chemokine/IFNg signature in KLRB1 and KLRB1þ CTLs based on the data from single-cell RNA sequencing. C, Coexpression of cytotoxic cytokines and inhibitory receptors on CD161 or CD161þ CTLs in OPSCC biopsies (n ¼ 13–19) via flow cytometry, paired Student t test. D, MFI of cytotoxic cytokines coexpressed on CD161 or CD161þ CTLs treated with PD-1 or CD39 blocking antibodies in OPSCC biopsies (n ¼ 7–8), paired Student t test. E, MFI of IFNg coexpressed on CD161þ CTLs treated with CD161-blocking antibodies for 72 hours in HPVþ biopsies (n ¼ 3) and blood samples (n ¼ 4), paired Student t test. , P < 0.05; , P < 0.01; , P < 0.001. n.s.: no statistical significance.
    Figure Legend Snippet: Figure 4. The phenotype and function of CD161þ CTLs. A, Heat map displaying expression values of discriminative genes between KLRB1 and KLRB1þ CTLs (from clusters 0, 2, 3, and 9) based on the data from single-cell RNA sequencing. B, Scores for the terminal exhaustion signature, tissue-resident memory T-cell signature, and chemokine/IFNg signature in KLRB1 and KLRB1þ CTLs based on the data from single-cell RNA sequencing. C, Coexpression of cytotoxic cytokines and inhibitory receptors on CD161 or CD161þ CTLs in OPSCC biopsies (n ¼ 13–19) via flow cytometry, paired Student t test. D, MFI of cytotoxic cytokines coexpressed on CD161 or CD161þ CTLs treated with PD-1 or CD39 blocking antibodies in OPSCC biopsies (n ¼ 7–8), paired Student t test. E, MFI of IFNg coexpressed on CD161þ CTLs treated with CD161-blocking antibodies for 72 hours in HPVþ biopsies (n ¼ 3) and blood samples (n ¼ 4), paired Student t test. , P < 0.05; , P < 0.01; , P < 0.001. n.s.: no statistical significance.

    Techniques Used: Expressing, RNA Sequencing, Cytometry, Blocking Assay



    Similar Products

    cd39 blockingmab  (Bio-Rad)
    94
    Bio-Rad cd39 blockingmab
    Figure 4. The phenotype and function of CD161þ CTLs. A, Heat map displaying expression values of discriminative genes between KLRB1 and KLRB1þ CTLs (from clusters 0, 2, 3, and 9) based on the data from single-cell RNA sequencing. B, Scores for the terminal exhaustion signature, tissue-resident memory T-cell signature, and chemokine/IFNg signature in KLRB1 and KLRB1þ CTLs based on the data from single-cell RNA sequencing. C, Coexpression of cytotoxic cytokines and inhibitory receptors on CD161 or CD161þ CTLs in OPSCC biopsies (n ¼ 13–19) via flow cytometry, paired Student t test. D, MFI of cytotoxic cytokines coexpressed on CD161 or CD161þ CTLs treated with PD-1 or <t>CD39</t> blocking antibodies in OPSCC biopsies (n ¼ 7–8), paired Student t test. E, MFI of IFNg coexpressed on CD161þ CTLs treated with CD161-blocking antibodies for 72 hours in HPVþ biopsies (n ¼ 3) and blood samples (n ¼ 4), paired Student t test. , P < 0.05; , P < 0.01; , P < 0.001. n.s.: no statistical significance.
    Cd39 Blockingmab, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd39 blockingmab/product/Bio-Rad
    Average 94 stars, based on 1 article reviews
    cd39 blockingmab - by Bioz Stars, 2026-05
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    Figure 4. The phenotype and function of CD161þ CTLs. A, Heat map displaying expression values of discriminative genes between KLRB1 and KLRB1þ CTLs (from clusters 0, 2, 3, and 9) based on the data from single-cell RNA sequencing. B, Scores for the terminal exhaustion signature, tissue-resident memory T-cell signature, and chemokine/IFNg signature in KLRB1 and KLRB1þ CTLs based on the data from single-cell RNA sequencing. C, Coexpression of cytotoxic cytokines and inhibitory receptors on CD161 or CD161þ CTLs in OPSCC biopsies (n ¼ 13–19) via flow cytometry, paired Student t test. D, MFI of cytotoxic cytokines coexpressed on CD161 or CD161þ CTLs treated with PD-1 or CD39 blocking antibodies in OPSCC biopsies (n ¼ 7–8), paired Student t test. E, MFI of IFNg coexpressed on CD161þ CTLs treated with CD161-blocking antibodies for 72 hours in HPVþ biopsies (n ¼ 3) and blood samples (n ¼ 4), paired Student t test. , P < 0.05; , P < 0.01; , P < 0.001. n.s.: no statistical significance.

    Journal: Cancer Immunology Research

    Article Title: CD161 characterizes an inflamed subset of cytotoxic T lymphocytes associated with prolonged survival in human papillomavirus-driven oropharyngeal cancer

    doi: 10.1158/2326-6066.cir-22-0454

    Figure Lengend Snippet: Figure 4. The phenotype and function of CD161þ CTLs. A, Heat map displaying expression values of discriminative genes between KLRB1 and KLRB1þ CTLs (from clusters 0, 2, 3, and 9) based on the data from single-cell RNA sequencing. B, Scores for the terminal exhaustion signature, tissue-resident memory T-cell signature, and chemokine/IFNg signature in KLRB1 and KLRB1þ CTLs based on the data from single-cell RNA sequencing. C, Coexpression of cytotoxic cytokines and inhibitory receptors on CD161 or CD161þ CTLs in OPSCC biopsies (n ¼ 13–19) via flow cytometry, paired Student t test. D, MFI of cytotoxic cytokines coexpressed on CD161 or CD161þ CTLs treated with PD-1 or CD39 blocking antibodies in OPSCC biopsies (n ¼ 7–8), paired Student t test. E, MFI of IFNg coexpressed on CD161þ CTLs treated with CD161-blocking antibodies for 72 hours in HPVþ biopsies (n ¼ 3) and blood samples (n ¼ 4), paired Student t test. , P < 0.05; , P < 0.01; , P < 0.001. n.s.: no statistical significance.

    Article Snippet: For the checkpoint blockade experiment, cryopreservated TILs or PBMCs were thawed, expanded, and seeded (5 105 cells/well) as described, and treated with PD-1 blocking monoclonal antibody (mAb; BioLegend, clone EH12.2H7, cat. #329926, 10 mg/mL), CD39 blockingmAb (Bio-Rad, clone A1, cat. #MCA1268EL, 10 mg/mL), or Tim-3 blocking mAb (BioLegend, clone F28-2E2, cat. #345004, 10 mg/mL) for 7 days.

    Techniques: Expressing, RNA Sequencing, Cytometry, Blocking Assay